ArticleCancers2021
Recurrent Mutations in
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.BMC cancer · 2022Pooled it
- Are current Polish guidelines for prophylactic mastectomy sufficient?Hereditary cancer in clinical practice · 2026Review
- Article
- Hereditary ovarian cancer.Discover oncology · 2026Review
- Hereditary cancer syndromes with gynecological cancer risk: focus on prevention strategies.Frontiers in oncology · 2026Review
- GermlineCurrent oncology (Toronto, Ont.) · 2025Article
- Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial.Trials · 2025Article
- Establishment of Novel High-Grade Serous Ovarian Carcinoma Cell Line OVAR79.International journal of molecular sciences · 2024Article
- CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.The Journal of biological chemistry · 2024Article
- Exploring the causal role of multiple metabolites on ovarian cancer: a two sample Mendelian randomization study.Journal of ovarian research · 2024Article
- Molecular landscape of borderline ovarian tumours: A systematic review.Open medicine (Warsaw, Poland) · 2024Review
- Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- TheGenes · 2023Article
- Genetic testing for hereditary breast cancer in Poland: 1998-2022.Hereditary cancer in clinical practice · 2023Article
- Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence.Metabolites · 2023Review
- Genetic diversity in Kashubs: the regional increase in the frequency of several disease-causing variants.Journal of applied genetics · 2022Review
- Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.BMC cancer · 2022Article
- Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor.Hereditary cancer in clinical practice · 2022Article
- Case Report Series: Aggressive HR Deficient Colorectal Cancers Related to BRCA1 Pathogenic Germline Variants.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 7 institutions in 2 countries.
Alicja ŁukomskaDepartment of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.
Janusz MenkiszakDepartment of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland.
Jacek GronwaldDepartment of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.ORCID 0000-0002-3643-2871
Joanna Tomiczek-SzwiecDepartment of Histology, Department of Biology and Genetics, Faculty of Medicine, University of Opole, 45-040 Opole, Poland.
Marek SzwiecDepartment of Surgery and Oncology, University of Zielona Góra, 65-046 Zielona Góra, Poland.
Marek JasiówkaDepartment of Chemotherapy Ludwik Rydygier Memorial Specialist Hospital, Zlotej Jesieni 1, 31-820 Krakow, Poland.
Paweł BlecharzDepartment of Gynaecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, 31-115 Krakow, Poland.
Tomasz KluzDepartment of Gynecology and Obstetrics, Institute of Medical, Sciences, Medical College of Rzeszow University, 35-959 Rzeszow, Poland.ORCID 0000-0002-4798-3986
Małgorzata Stawicka-NiełacnaDepartment of Clinical Genetics and Pathology University of Zielona Góra, 65-046 Zielona Góra, Poland.
Radosław MądryDepartment of Gynecological Oncology, Poznan University of Medical Science, 60-569 Poznań, Poland.ORCID 0000-0003-0738-2788
Katarzyna BiałkowskaDepartment of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.
Karolina PrajzendancDepartment of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.
Wojciech KluźniakDepartment of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.
Cezary CybulskiDepartment of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.ORCID 0000-0002-2819-3057
Tadeusz DębniakDepartment of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.
Tomasz HuzarskiDepartment of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.ORCID 0000-0003-3857-4854
Aleksandra Tołoczko-GrabarekDepartment of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.
Tomasz ByrskiDepartment of Oncology and Chemotherapy, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland.
Piotr BaszukDepartment of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.
Steven A NarodWomen's College Research Institute, Toronto, ON M5S 1B2, Canada.
Jan LubińskiDepartment of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.
Anna JakubowskaDepartment of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.ORCID 0000-0002-5650-0501
Pomeranian Medical University · PLUniversity of Zielona Góra · PLPoznan University of Medical Sciences · PLThe Maria Sklodowska-Curie National Research Institute of Oncology · PLUniversity of Opole · PLUniversity of Rzeszów · PLWomen's College Hospital · CA
Funding
Ministerstwo Nauki i Szkolnictwa Wyższego "Regional Initiative of Excellence" in 2019-2022 project number 002/RID/2018/19; amount of financing 12 000 000 PLN
Abstract
The aim of the study was to analyze the frequency and magnitude of association of 21 recurrent founder germline mutations in
Indexed as
BRCA1BRCA2cancer riskCHEK2ovarian cancerPALB2RAD51Crecurrent mutations
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.